News & Trends - MedTech & Diagnostics
Life rewired: Medtronic’s global leader talks precision and the expanding potential of DBS in neurological disorders

Deep brain stimulation (DBS) is an established treatment for neurological and movement disorders such as Parkinson’s disease, tremor and dystonia, with a potential for expansion in psychiatric indications.
In an exclusive interview, international guest Amaza Reitmeier, Vice President and General Manager of Brain Modulation at Medtronic, sheds light on the evolving landscape of DBS.
The development of DBS technology has undergone profound shifts over the last 30 years, particularly in terms of device sophistication, precision and “restoring hope in daily life”. However, despite DBS’ established track record, Reitmeier highlighted a significant lag where the technology remains underutilised and may be considered as a “last resort”.
She addressed two key challenges faced by clinicians and patients that limit the delivery of equitable access to DBS, noting that these complexities are not unique to the Australian market.
Looking to the future, Reitmeier discussed the potential of artificial intelligence (AI) and adaptive DBS to advance personalised treatment. The next frontier in DBS, she explained, lies in creating systems that can autonomously adjust stimulation parameters based on real-time data, thereby tailoring therapy to the individual needs of each patient.
Medtronic is investing heavily in research and development to unlock new applications for DBS. The possibilities are vast as this medtech company pushes the boundaries of what DBS can achieve, ultimately bringing hope to a broader range of patients, including those battling depression.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - Pharmaceuticals

New combination therapy improves survival rates for Aussies with advanced prostate cancer
A world-first treatment approach has demonstrated significant advancements in the management of metastatic castration-resistant prostate cancer (mCRPC) compared to conventional […]
MoreNews & Trends - Pharmaceuticals

‘Don’t just learn what illness is, learn what it feels like,’ Dr Ben Bravery
With the iconic Sydney Harbour as a backdrop, the Merck Healthcare team came together for a dynamic and engaging kick-off […]
MoreNews & Trends - MedTech & Diagnostics

GE HealthCare, Lumus Imaging and GenesisCare unite to bring advanced technology to patients
GE HealthCare and Lumus Imaging have joined forces to enhance medical care in Sydney’s Campbelltown region, unveiling a state-of-the-art imaging […]
MoreNews & Trends - MedTech & Diagnostics

World-First mobile CT for regional healthcare
An Australian X-ray technology company developing a world-first full-body mobile CT following the award of an up to US$16.4m (A$25m) […]
More